Market volatility derails Novartis' plan to sell stake in its India arm
Novartis AG's plan to sell its 70.68% stake in Novartis India faces challenges due to market volatility impacting valuation.
Medical Marketing & Media1d
Novartis names new chief legal and compliance officer as Klaus Moosmayer exits
Karen Hale, who joined Novartis in 2021 as chief legal officer, will take on the new chief legal and compliance officer role.
TMCnet3h
Grove AI Welcomes Former Novartis, UCB, and Google Executives to Company Advisory Board
The Grove AI Advisory Board brings together distinguished experts in global pharmaceutical strategy, AI innovation, and regulatory compliance. Advisory members will collaborate directly with Grove ...
Fierce Pharma4d
Novartis' prostate cancer drug Pluvicto wins key FDA nod toward $5B-plus sales target
After much delay, Novartis has finally won a key FDA go-ahead for Pluvicto, opening up the radioligand therapy to a much ...
BioPharma Dive4d
FDA broadens use of Novartis’ radiopharma drug Pluvicto
Pluvicto can now be used before chemotherapy to treat a kind of metastatic prostate cancer, tripling the number of patients ...
Fierce Pharma12d
Novartis snags FDA nod for Fabhalta in another kidney disease but leaves room for rival Apellis
Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts ...
Barclays Reaffirms Their Sell Rating on Novartis AG (NOVN)
In a report released today, Emily Field from Barclays maintained a Sell rating on Novartis AG (NOVN – Research Report), with a price target of ...
Pharmabiz2d
Novartis radioligand therapy, Pluvicto gets US FDA approval for earlier use before chemotherapy in PSMA-positive mCRPC
Novartis radioligand therapy, Pluvicto gets US FDA approval for earlier use before chemotherapy in PSMA-positive mCRPC: Basel Monday, March 31, 2025, 13:00 Hrs [IST] Novartis anno ...
Yahoo Finance13d
Novartis builds case for new SMA gene therapy
To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. On Wednesday, Novartis gave a more ...
Medical Dialogues2d
Novartis appoints Karen Hale as Chief Legal and Compliance Officer
Basel: Novartis has announced the appointment of Karen Hale to the expanded role of Chief Legal and Compliance Officer for ...
Novartis12d
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)
Basel, March 20, 2025 – Novartis today announced that oral Fabhalta ® (iptacopan) has received U.S. Food and Drug Administration (FDA) approval for the treatment of adults with C3 glomerulopathy (C3G) ...